• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BrainStorm seeks early Health Canada nod for NurOwn treatment

February 22, 2017 By Sarah Faulkner

BrainStorm seeks early Health Canada nod for NurOwn treatmentBrainstorm Cell Therapeutics (NSDQ:BCLI) is reportedly seeking early regulatory approval in Canada for its NurOwn stem cell treatment for patients with ALS.

The company told Reuters this week that it has inked an agreement with a Canadian non-profit organization, CCRM, that helps to support the development of regenerative medicine. The organization plans to help BrainStorm meet Canadian regulatory requirements for the early access pathway, which would speed up the treatment’s review process.

If NurOwn qualifies for the rapid review pathway, it could be authorized for distribution in Canada by the beginning of next year, BrainStorm told the news outlet.

“We seemingly fit the criteria,” CEO Chaim Lebovits said.

In December last year, the Israel-based company said it’s preparing for a phase III trial of its stem cell treatment at multiple sites across the U.S. and in Israel. The trial is slated to enroll patients in the 2nd quarter of this year.

BrainStorm is also looking to submit a “Hospital Exemption” application in Israel to allow patient access to NurOwn at a particular medical center. The recently approved pathway would enable BrainStorm to treat patients with its stem cell therapy for a fee.

Lebovits told Reuters that the company could be providing treatments under this pathway as early as the 2nd half of this year.

Filed Under: Featured, Regulatory/Compliance, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS